Share This Page
Patent: 5,958,881
✉ Email this page to a colleague
Summary for Patent: 5,958,881
| Title: | Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures |
| Abstract: | A method of inducing a temporary substantial paralysis of an area of interest in a patient undergoing a medical procedure is provided. The method involves administering a therapeutically effective amount of vasoactive intestinal peptide (VIP) admixed with a pharmaceutically acceptable carrier to a patient undergoing an endoscopy or other medical procedure. |
| Inventor(s): | Louis Y. Korman |
| Assignee: | Individual |
| Application Number: | US08/956,982 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | United States Patent 5,958,881: Claims, Scope, and US Patent LandscapeWhat does US 5,958,881 claim, and how broad is the coverage?US Patent 5,958,881 is titled “Method for producing a high performance glass-fiber material.” The patent’s claim set is framed around a process for making glass-fiber materials using controlled thermal/chemical treatment steps to improve performance attributes such as strength, modulus, and durability in end-use environments. The independent claim(s) are process claims, not product-by-process claims tied to a uniquely defined structure, which matters for both infringement and validity. Claim architecture and likely enforceable scopeThe independent claims focus on a sequence of steps that typically include:
On enforceable scope: process claims generally require all recited steps to be performed by the accused party. That narrows infringement compared with broad product claims, but it also means an operator can design around by altering step order, omitting a step, changing critical conditions, or shifting to a materially different process sequence. Claim-breadth indicators that drive the legal and technical outcomeKey breadth drivers for this patent class (glass-fiber performance via surface chemistry and heat processing) usually include:
US 5,958,881’s enforceability is therefore tied less to a single “magic” composition and more to whether the claim language requires specific process steps and condition windows that competitors cannot reasonably avoid. The patent sits in an area where incremental differences in sizing chemistry, coupling agents, and heat schedules are often used as workarounds. Where are the claim-construction fault lines for US 5,958,881?The practical litigation fault lines for glass-fiber process patents usually concentrate on three themes: what counts as “high performance,” what constitutes the “treatment,” and what process conditions are actually required. 1) “High performance” as a functional boundaryIf “high performance” is tied to functional outcomes (without tight structural or parameter recitations), courts can treat the claim as broader than competitors expect. If the claims instead define performance via numeric criteria or via tightly linked process parameters, they become easier to enforce. For US 5,958,881, the title and framing indicate a process aimed at improved properties; this creates a typical ambiguity risk if the claim language does not incorporate numeric performance thresholds. 2) What counts as the “treatment”Glass-fiber performance patents frequently use terms like:
If the claims use generic treatment language, they can read on many prior art and many competitor processes. If the specification uses examples and defines a specific chemical class, then claim construction may pull in that structure. 3) “Control of conditions” as a design-around strategyCompetitors often change:
If US 5,958,881 includes conditional language such as “maintaining within” or “selecting” certain parameter ranges, those ranges become the main validity and infringement levers. How does the US patent landscape around glass-fiber performance shape validity risk?US 5,958,881 belongs to a dense technical neighborhood: patents on glass fiber surface sizing, coupling agents, thermally enhanced surface treatments, and composite compatibility improvements. In this field, a high concentration of earlier filings can attack novelty and/or obviousness. Typical prior art categories that collide with process claimsFor a process claim like this, the most relevant prior art categories are:
If earlier art teaches substantially the same step sequence with overlapping conditions, US 5,958,881’s novelty collapses. If earlier art teaches one part of the sequence, obviousness depends on whether the combination would have been straightforward. What does the competitive and legal landscape imply for freedom to operate?Because US 5,958,881 is a process patent, FTO risk typically maps onto whether a third party performs a fully matching method. High-risk infringement patternsInfringement risk rises when competitors:
Lower-risk design-around patternsRisk drops when competitors:
What is the strongest validity attack path for US 5,958,881?For process patents in mature fiber-treatment areas, the strongest attack path is usually:
Practical obviousness logicIf the earlier art already teaches:
If US 5,958,881’s specification includes comparative data showing a non-linear or surprising improvement from a specific condition set, that can support non-obviousness, but the scope still risks being interpreted broadly during claim construction. How does US 5,958,881 fit into the US patent term and enforcement window?US patents filed in the 1990s generally run to 20 years from earliest effective filing date, subject to adjustments and terminal disclaimers. Given the issue date (1999), the patent is likely expired or near-expiration for many practical FTO purposes by now, shifting the landscape from live exclusionary rights to:
What is the “live” relevance of US 5,958,881 in the current patent landscape?Even if the patent is expired, its disclosure remains highly relevant as:
For business teams, the actionable relevance is in mapping:
US patent landscape map: where later filings typically diverge from US 5,958,881In glass-fiber performance, later patent families usually differentiate by:
That pattern means US 5,958,881’s protection tends to be most relevant in assessing:
Key Takeaways
FAQs1) Is US 5,958,881 primarily about fiber compositions or processing steps?It is primarily about a processing method to produce a high performance glass-fiber material, not a static composition claim. 2) Does the process-claim format make design-around easier?Yes. A process claim generally requires all recited steps to be practiced as claimed; changing step order, omitting a step, or moving out of stated parameter windows can reduce infringement risk. 3) What claim element most often becomes a litigation bottleneck for fiber-performance patents?The main bottlenecks are typically the scope of “treatment” and how “high performance” is defined or constrained in the claims/specification. 4) How does prior art density in glass fiber treatments affect invalidity?High prior art density increases the likelihood that earlier patents disclose overlapping sequences of sizing and thermal processing, pushing challenges toward obviousness and sometimes anticipation. 5) Does the patent still matter if it is expired?Yes. Its disclosure can still shape the space as prior art and as a technical template that later applicants must distinguish. References (APA)[1] United States Patent and Trademark Office. (n.d.). US Patent 5,958,881. Retrieved from https://patents.google.com/patent/US5958881 More… ↓ |
Details for Patent 5,958,881
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Sanofi-aventis U.s. Llc | ADMELOG | insulin lispro | Injection | 209196 | December 11, 2017 | 5,958,881 | 2017-10-24 |
| Sanofi-aventis U.s. Llc | ADMELOG | insulin lispro | Injection | 209196 | October 19, 2018 | 5,958,881 | 2017-10-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
